In Viking Therapeutics, 16 investors hold a majority stake of 51%. Institutions are the largest shareholders with 74% ownership, influencing the company's performance. Insider ownership aligns with board decisions, while public investors hold 20% stake. Analyst forecasts and investment risks should also be considered.